Markets

Palantir upgraded to ‘buy’ with a fresh $34 price target from Goldman Sachs after revealing ‘sustainable growth’ in latest earnings

Palantir posted a surprise loss in its fiscal fourth-quarter earnings on Tuesday, causing the stock to fall. Goldman Sachs analysts thought the quarter was stronger than expected and raised their price target to $US34 per share. The analysts cheered Palantir’s government revenue, margin expansion, and backlog visibility. Sign up here […]
Palantir upgraded to ‘buy’ with a fresh $34 price target from Goldman Sachs after revealing ‘sustainable growth’ in latest earnings
Markets

Palantir surges 17% after it wins FDA contract worth $44 million, report says

Palantir surged as much as 17% on Monday after a Bloomberg report said the data-mining firm won a three-year contract with the FDA worth $US44 million. Palantir’s software will help drive the FDA’s drug reviews and inspections, according to the report. Visit Business Insider’s homepage for more stories. Palantir surged […]
Palantir surges 17% after it wins FDA contract worth $44 million, report says
Markets

Palantir will surge 31% as Wall Street realises potential for breakneck profit growth, Morgan Stanley says

Investors aren’t seeing the bigger picture regarding Palantir’s discounted valuation, Morgan Stanley analysts said Monday. The bank initiated an “overweight” rating on Palantir’s shares in a note to clients. The analysts’ $US13-per-share price target implies a 31% rally from Monday’s close over the next 12 months. Palantir closed Monday just […]
Palantir will surge 31% as Wall Street realises potential for breakneck profit growth, Morgan Stanley says